In the Czech Republic an application has been filed, so the use of The NGAL-Test can be covered by the public healthInsurance.
This means that the Czech Republic will be the FIRST country worldwide to adapt the NGAL Test in routine diagnostics (if the application is approved)
Hopefully we will soon be able to say : Congratulations Czech Citizens !!!
BioPorto Diagnostics is the sole player on the Czech marked, which is covered by the EPO Cutoff patent.
